PPMO's as therapeutic modulators for myotonic dystrophy type 1

Схожие документы

• Proteomic evaluation of Pip6a-PMO treatment for myotonic dystrophy type 1
  по: Holland, A, и др.
  Опубликовано: (2018)
• Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice
  по: Klein, AF, и др.
  Опубликовано: (2019)
• Application of antisense conjugates for the treatment of myotonic dystrophy type 1
  по: Stoodley, J, и др.
  Опубликовано: (2023)
• Systemic PPMO-mediated dystrophin expression in the Dup2 mouse model of Duchenne muscular dystrophy
  по: Liubov V. Gushchina, и др.
  Опубликовано: (2022-12-01)
• Cardiac manifestations in myotonic dystrophy type 1
  по: A. G. Klementieva, и др.
  Опубликовано: (2024-09-01)